Skip to main content
. 2020 Apr 10;10:6209. doi: 10.1038/s41598-020-63391-z

Table 1.

Clinicopathologic characteristics of patient groups in TCGA cohort.

YAP mRNA expression level P-value YAP Signature Score (GSVA) P-value
Low YAP expression High YAP expression Low YAP signature High YAP signature
Number of Patients 40 40 40 40
Age, years, Mean (SD) 63.0 (15.0) 61.4 (13.1) 0.62 64.9 (13.2) 59.5 (14.4) 0.09
Male, No. (%) 23 (57.5%) 22 (55%) 0.99 22 (55%) 23 (57.5%) 0.99
Basal diameter (mm)* 16.3 ± 3.8 16.8 ± 3.8 0.72 15.9 ± 3.7 17.2 ± 3.9 0.13
Thickness (mm)* 10.3 ± 2.7 10.5 ± 2.9 0.7 10.3 ± 2.6 10.5 ± 3.0 0.79
AJCC stage (8th edition)
   Stage IIA, No. (%) 3 (7.5%) 1 (2.5%) 0.9 3 (7.5%) 1 (2.5%) 0.6
   Stage IIB, No. (%) 17 (42.5%) 15 (37.5%) 17 (42.5%) 15 (37.5%)
   Stage IIIA, No. (%) 12 (30%) 15 (37.5%) 10 (25%) 17 (42.5%)
   Stage IIIB, No. (%) 5 (12.5%) 5 (12.5%) 6 (15%) 4 (10%)
   Stage IIIC, No. (%) 1 (2.5%) 2 (5%) 2 (5%) 1 (2.5%)
   Stage IV, No. (%) 2 (5%) 2 (5%) 2 (5%) 2 (5%)
Dominant cell types
   Spindle, No. (%) 34 (85%) 23 (57.5%) 0.013 33 (82.5%) 24 (60%) 0.047
   Epithelioid, No. (%) 6 (15%) 17 (42.5%) 7 (17.5%) 16 (40%)
Pigmentation
   Minimal, No. (%) 14 (35%) 25 (62.5%) 0.025 19 (47.5%) 20 (50%) 0.99
   Marked, No. (%) 26 (65%) 15 (37.5%) 21 (52.5%) 20 (50%)
Mitotic count
   0-5/HPF, No. (%) 32 (80%) 31 (77.5%) 0.84 34 (85%) 29 (72.5%) 0.42
   5-10/HPF, No. (%) 6 (15%) 5 (12.5%) 4 (10%) 7 (17.5%)
   >11/HPF, No. (%) 2 (5%) 4 (10%) 2 (5%) 4 (10%)
GNAQ/11 mutation, No. (%) 37 (92.5%) 36 (90%) 0.99 38 (95%) 35 (87.5%) 0.43
BAP1 mutation, No. (%) 13 (32.5%) 22 (55%) 0.07 13 (32.5%) 22 (55%) 0.07
EIF1AX mutation, No. (%) 6 (15%) 4 (10%) 0.74 6 (15%) 4 (10%) 0.74
SF3B1 mutation, No. (%) 11 (27.5%) 7 (17.5%) 0.42 13 (32.5%) 5 (12.5%) 0.06

SD = standard deviation, No. = Number, AJCC = American Joint Committee on Cancer.

*Data are presented as mean ± standard deviation.